Treatment News
-
Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor's Novel Cell Therapy
Friday, January 25, 2019LOS ANGELES, USA - Neurology(R), an international peer-reviewed journal, published the results of the HOPE-Duchenne clinical trial that evaluated the safety and efficacy of a single intracoronary dose of Capricor Therape... -
First Mesothelioma Patient Dosed in CA-170 Study
Friday, January 25, 2019LEXINGTON, Mass. - Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the first mesothelioma patient has been enrolled an... -
Remote Participation Enables Patients with ALK-Positive Lung Cancer from Across the Country to Participate in New Study of Treatment Resistance
Friday, January 25, 2019SAN CARLOS, Calif. - The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, and researchers from the Dana-Farber Cancer Institute are launching a novel nationwide ... -
Targeted Treatment Shrinks Deadly Pediatric Brain Tumors
Thursday, January 24, 2019LA JOLLA, CA - Chemotherapy and radiation are effective cancer treatments because they kill rapidly dividing cells, including tumor cells. But for children--whose tiny bodies are still growing--these treatments can cause... -
Can India Lead The Way in Neglected Diseases Innovation?
Thursday, January 24, 2019Nirmal Kumar Ganguly and colleaguescall for a comprehensive policy for neglected diseases research in India to foster innovation in drugs, diagnostics, and vaccines, critical for evolving needs of elimination programmesI... -
Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers
Thursday, January 24, 2019ZUG, Switzerland - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, hi... -
Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs
Thursday, January 24, 2019Princeton, NJ - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ... -
Orkambi Approved in Europe for Younger CF Patients with F508del Mutations
Thursday, January 24, 2019The European Commission has approved the label extension of Orkambi (lumacaftor/ivacaftor) for the treatment of children ages 2-5 with cystic fibrosis (CF) due to F508del mutations, Vertex Pharmaceuticals, the therapy's ... -
FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
Wednesday, January 23, 2019ROCKVILLE, Md. - Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced... -
Albireo Granted Orphan Drug Designation by FDA For Lead Product Candidate A4250 for Treatment of Biliary Atresia
Wednesday, January 23, 2019BOSTON, Ma. - Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced the U.S. Food and Drug Administration (FDA) has granted orphan d...